

## Hemovigilance Module Adverse Reaction

*Required for saving					
*Facility ID#: NHSN Ac	dverse Reaction #:				
Patient Information					
*Patient ID:					
Social Security #:	Secondary ID: Medicare #:				
Last Name:	First Name: Middle Name:				
Ethnicity 🗌 Hispanic or Latino	Not Hispanic or Not Latino				
Race American Indian/Alaska Native Asian Black or African American					
Native Hawaiian/Othe					
*Blood Group: 🗌 A- 🗌 A+ 🗌 E	B- □B+ □ AB- □ AB+ □ O- □ O+ □ Blood type not done				
	Rh +				
	B/Transitional Rh Group O/Transitional Rh Group AB/Transitional Rh				
Patient Medical History					
	sis. (Use ICD-10 Diagnostic codes/descriptions)				
Code:	Description:				
Code:	Description:				
Code:	Description:				
List the patient's underlying indica	tion for transfusion. (Use ICD-10 Diagnostic codes/descriptions)				
Code:	Description:				
Code:	Description:				
Code:	Description:				
List the patient's comorbid condition reaction. (Use ICD-10 Diagnostic	ons at the time of the transfusion related to the adverseUNKNOWNcodes/descriptions)NONE				
Code:	Description:				
Code:	Description:				
Code:	Description:				
of any individual or institution is collected w stated, and will not otherwise be disclosed	ly provided information obtained in this surveillance system that would permit identification ith a guarantee that it will be held in strict confidence, will be used only for the purposes or released without the consent of the individual, or the institution in accordance with Health Service Act (42 USC 242b, 242k, and 242m(d)).				
reviewing instructions, searching existing d collection of information. An agency may n unless it displays a currently valid OMB cor	information is estimated to average 20 minutes per response, including the time for ata sources, gathering and maintaining the data needed, and completing and reviewing the ot conduct or sponsor, and a person is not required to respond to a collection of information atrol number. Send comments regarding this burden estimate or any other aspect of this ons for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, b).				

National Healthcare Safety Network

	nedical procedure including past procedures and procedures to be nt hospital or outpatient stay. <i>(Use ICD-10 Procedure</i>	UNKNOWN
Code:	Description:	
Code:	Description:	
Code:	Description:	
Additional Information		
Transfusion History		
Has the patient received a	previous transfusion?	IKNOWN
Blood Product:	WB RBC Platelet Plasma Cryoprecipitate	Granulocyte
Date of Transfusion:		
·	e reaction transfusion-related?	
• •	about the transfusion adverse reaction.	<u> </u>
	rse reaction:	
	fy	
Reaction Details		
	// *Time reaction occurred::	INKNOWN
*Facility location where patie Is this reaction associated with		
is this reaction associated with		
Investigation Desults		
Investigation Results	graft vs. bost dispase (TA-GV/HD)	
* Transfusion associated	graft vs. host disease (TA-GVHD)	
* Transfusion associated *Case Definition		
* Transfusion associated *Case Definition	graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction?	Yes No
* Transfusion associated *Case Definition Did patient receive non-irra Check all that occurred w		□ Yes □ No
* Transfusion associated *Case Definition Did patient receive non-irra Check all that occurred w Clinical syndrome	adiated blood product(s) in the two months preceding the reaction?	
* Transfusion associated *Case Definition Did patient receive non-irra Check all that occurred w Clinical syndrome Clinical syndrome	radiated blood product(s) in the two months preceding the reaction? <b>vithin 2 days to 6 weeks</b> after cessation of transfusion: e characteristics:  Diarrhea  Fever  Hepatomegaly	Pancytopenia
* Transfusion associated *Case Definition Did patient receive non-irra Check all that occurred w Clinical syndrome Clinical syndrome Liver dysfunction	radiated blood product(s) in the two months preceding the reaction? <b>vithin 2 days to 6 weeks</b> after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly [ ion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin)	☐ Pancytopenia ☐ Marrow aplasia
* Transfusion associated *Case Definition Did patient receive non-irra Check all that occurred w Clinical syndrome Clinical syndrome Liver dysfunction Characteristic	adiated blood product(s) in the two months preceding the reaction? <b>vithin 2 days to 6 weeks</b> after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly [ tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) [ rash: erythematous, maculopapular eruption centrally that spreads	<ul> <li>Pancytopenia</li> <li>Marrow aplasia</li> <li>to extremities and</li> </ul>
* Transfusion associated *Case Definition Did patient receive non-irra Check all that occurred w Clinical syndrome Clinical syndrome Liver dysfunction Characteristic may, in severe cast	radiated blood product(s) in the two months preceding the reaction? <b>vithin 2 days to 6 weeks</b> after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly [ ion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin)	<ul> <li>Pancytopenia</li> <li>Marrow aplasia</li> <li>to extremities and</li> </ul>
<ul> <li>Transfusion associated</li> <li>*Case Definition         <ul> <li>Did patient receive non-irra</li> <li>Check all that occurred w</li> <li>Clinical syndrome</li> <li>Clinical syndrome</li> <li>Liver dysfunction</li> <li>Characteristic may, in severe car</li> </ul> </li> <li>Check all that apply:</li> </ul>	radiated blood product(s) in the two months preceding the reaction? <b>vithin 2 days to 6 weeks</b> after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly [ ion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) [ rash: erythematous, maculopapular eruption centrally that spreads ases, progress to generalized erythroderma and hemorrhagic bullou	<ul> <li>Pancytopenia</li> <li>Marrow aplasia</li> <li>to extremities and</li> </ul>
<ul> <li>Transfusion associated</li> <li>*Case Definition         <ul> <li>Did patient receive non-irration</li> <li>Did patient receive non-irration</li> <li>Check all that occurred w</li></ul></li></ul>	radiated blood product(s) in the two months preceding the reaction? <b>vithin 2 days to 6 weeks</b> after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly [ tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) [ rash: erythematous, maculopapular eruption centrally that spreads ases, progress to generalized erythroderma and hemorrhagic bullou bgical appearance of skin or liver biopsy.	<ul> <li>Pancytopenia</li> <li>Marrow aplasia</li> <li>to extremities and</li> </ul>
<ul> <li>Transfusion associated</li> <li>*Case Definition         <ul> <li>Did patient receive non-irration</li> <li>Did patient receive non-irration</li> <li>Check all that occurred w</li></ul></li></ul>	radiated blood product(s) in the two months preceding the reaction? <b>vithin 2 days to 6 weeks</b> after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly [ tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) [ rash: erythematous, maculopapular eruption centrally that spreads ases, progress to generalized erythroderma and hemorrhagic bullou bgical appearance of skin or liver biopsy. not done.	<ul> <li>Pancytopenia</li> <li>Marrow aplasia</li> <li>to extremities and</li> </ul>
<ul> <li>Transfusion associated</li> <li>*Case Definition         <ul> <li>Did patient receive non-irra</li> <li>Check all that occurred w</li> <li>Clinical syndrome</li> <li>Clinical syndrome</li> <li>Liver dysfunction</li> <li>Characteristic may, in severe case</li> </ul> </li> <li>Check all that apply:         <ul> <li>Characteristic histolo</li> <li>Biopsy negative or n</li> <li>Other signs and symptoms:</li> </ul> </li> </ul>	radiated blood product(s) in the two months preceding the reaction? <b>vithin 2 days to 6 weeks</b> after cessation of transfusion: e characteristics: Diarrhea Pever Hepatomegaly [ ion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) [ e rash: erythematous, maculopapular eruption centrally that spreads ases, progress to generalized erythroderma and hemorrhagic bullou bgical appearance of skin or liver biopsy. hot done. : (check all that apply)	<ul> <li>Pancytopenia</li> <li>Marrow aplasia</li> <li>to extremities and</li> </ul>
<ul> <li>Transfusion associated</li> <li>*Case Definition         <ul> <li>Did patient receive non-irration</li> <li>Did patient receive non-irration</li> <li>Check all that occurred w</li></ul></li></ul>	radiated blood product(s) in the two months preceding the reaction?         vithin 2 days to 6 weeks after cessation of transfusion:         e characteristics:       Diarrhea       Fever       Hepatomegaly       [         ion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin)       [         e rash: erythematous, maculopapular eruption centrally that spreads ases, progress to generalized erythroderma and hemorrhagic bullou         opical appearance of skin or liver biopsy.         ot done.         : (check all that apply)         Chills/rigors       Nausea/vomiting	<ul> <li>Pancytopenia</li> <li>Marrow aplasia</li> <li>to extremities and</li> </ul>
<ul> <li>Transfusion associated</li> <li>*Case Definition         <ul> <li>Did patient receive non-irra</li> <li>Check all that occurred w</li> <li>Clinical syndrome</li> <li>Clinical syndrome</li> <li>Liver dysfunction</li> <li>Characteristic may, in severe case</li> </ul> </li> <li>Check all that apply:         <ul> <li>Characteristic histolo</li> <li>Biopsy negative or n</li> <li>Other signs and symptoms:</li> </ul> </li> </ul>	adiated blood product(s) in the two months preceding the reaction?   vithin 2 days to 6 weeks after cessation of transfusion:   e characteristics:   Diarrhea   Fever   Hepatomegaly   ion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin)   e rash: erythematous, maculopapular eruption centrally that spreads ases, progress to generalized erythroderma and hemorrhagic bullou   ogical appearance of skin or liver biopsy.   ot done.   : (check all that apply)   Chills/rigors   Blood pressure decrease	<ul> <li>Pancytopenia</li> <li>Marrow aplasia</li> <li>to extremities and</li> </ul>
<ul> <li>Transfusion associated</li> <li>*Case Definition         <ul> <li>Did patient receive non-irration</li> <li>Did patient receive non-irration</li> <li>Check all that occurred w</li></ul></li></ul>	radiated blood product(s) in the two months preceding the reaction?         vithin 2 days to 6 weeks after cessation of transfusion:         e characteristics:       Diarrhea       Fever       Hepatomegaly       [         ion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin)       [         e rash: erythematous, maculopapular eruption centrally that spreads ases, progress to generalized erythroderma and hemorrhagic bullou         opical appearance of skin or liver biopsy.         ot done.         : (check all that apply)         Chills/rigors       Nausea/vomiting	Pancytopenia Marrow aplasia to extremities and us formation.

	HSN
Na	tional Healthcare

Hemolysis/Hemorrhage:	Disseminated intra	0	tion 🗌 Hemoglobir	nemia		
	Positive antibody screen					
Pain:	Abdominal pain	Back pain		Infusion site pain		
Renal:	Hematuria	Hemoglobin				
Respiratory:	Bronchospasm	Cough	Shortness of	of breath		
Other: (specify)						
*Severity						
Did the patient receive o	r experience any of the	following?				
🗌 No treatment requ	ired	Symptomatio	c treatment only			
Hospitalization, in	lcuding prolonged hospi	italization	Life-threatening	reaction		
Disability and/or ir	capacitation	Congenital a	nomaly or birth defect(s)	) of the fetus		
Other medically in	nportant conditions	Death	🗌 Unknown or no	t stated		
*Imputability						
Which best describes the	relationship between th	ne transfusion and	the reaction?			
No other alternative	e diagnoses.					
Other potential cau	ises are present (e.g., s	tem cell transplan	tation).			
Alternative explana	tions are more likely (e.	.g., solid organ tra	insplantation).			
Evidence is clearly	in favor of a cause othe	r than the transfu	sion, but transfusion can	not be excluded.		
There is conclusive	evidence beyond reaso	onable doubt of a	cause other than the trar	nsfusion		
	•		fusion is unknown or not			
Did the transfusion occur		YES 🗌 NO				
WBC chimerism:	] WBC chimerism prese	ent 🗌 WE	C chimerism not presen	t or not done		
Module-generated Desig	anations					
NOTE: Designations for case	definition, severity, and			d in the NHSN		
application based on respons	es in the corresponding	g investigation res	ults section above.			
*Do you agree with the	case definition design	nation?	🗌 YES	□ NO		
Please indicate your de	signation					
*Do you agree with the	severity designation?	)	🗌 YES	□ NO		
Please indicate your de	signation					
*Do you agree with the	imputability designati	ion?	🗌 YES	□ NO		
^Please indicate your de	signation					
Patient Treatment						
Did the patient receive trea	itment for the transfusio	on reaction?	🗌 YES 🛛 NO			
If yes, select treatment(s)	:					
Medication (Select	the type of medication)					
Antipyretics Antihistamines Inotropes/Vasopressors Bronchodilator Diuretics						
🗌 Intravenous Immunoglobulin 🗌 Intravenous steroids 🛛 Corticosteroids 🗌 Antibiotics						
Antithymocyte globulin Cyclosporin Other						
🗌 Volume resuscitatio	on (Intravenous colloids	or crystalloids)				
CDC 57.316 Rev.2, v9.2	Page 3 c	-				
000 01.010 1.01.2, 10.2	1 age 5 t					

NHSN       Form Approved         National Healthcare       OMB No. 0920-0666         Exp. Date: 12/31/22       www.cdc.gov/nhsn									
Respiratory support <i>(Select the type of support)</i> Mechanical ventilation Noninvasive ventilation Oxygen									
Ren	al replacement therap ] Hemodialysis 🏾 🗍 F				o-Venous Hem	ofiltratio	n		
Phle	botomy er Specify:								
Outcome									
*Outcome: Death Major or long-term sequelae Minor or no sequelae Not determined Date of Death:/									
Component	Details								
	cular unit implicated	d in (i.e., respo		-	dverse	Ye	s 🗌	No [	] N/A
Transfusion Start and <b>End</b> Date/Time	*Component code (check system used)	Amount transfused at reaction onset	^Unit number (Required for Infection and t TRALI)		*Unit expiration Date/Time	*Blood group		Implicat ed Unit?	
^IMPLICATED	UNIT								
// : // :	☐ ISBT-128 ☐ Codabar —— —— —— —— ——	☐ Entire unit ☐ Partial unit mL			/ :	□ A- □B+	□ A+ □ AB- □ O+	□ B- □ AB+ □ N/A	Y
// : //	☐ ISBT-128 ☐ Codabar — — — — — —	Entire unit Partial unit mL	 	·	// :	□ A- □B+ □ 0-	□ A+ □ AB- □ O+	□ B- □ AB+ □ N/A	N
Custom Field	ls								
Label				Label					
	/	<u> </u>	-				/	/	
Comments									

All a little